Table 3.
Half-maximal inhibitory concentration (IC50 in μM; mean ± SD) for each cocktail substrate using different inhibitors
| Inhibitors |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
| Fenoterol | Sumatriptan | Ipratropium | Trospium | Metformin | Trimethoprim | Verapamil | Quinidine | ||
| Substrates | Fenoterol | 482 ± 42.9 | 22.4 ± 2.84 | 15.8 ± 1.87 | 9270 ± 954 | 45.0 ± 3.45 | 4.26 ± 0.63 | 16.3 ± 1.83 | |
| Salbutamol | 0.78 ± 0.12 | 628 ± 54.8 | 14.3 ± 2.66 | 8.14 ± 2.12 | 8882 ± 760 | 37.5 ± 7.77 | 1.48 ± 0.18 | 6.22 ± 1.48 | |
| Sumatriptan | 5.05 ± 0.57 | 51.4 ± 1.95 | 16.8 ± 2.03 | 3277 ± 575 | 12.0 ± 2.88 | 8.40 ± 0.82 | 25.2 ± 2.62 | ||
| Zolmitriptan | 0.95 ± 0.15 | 506 ± 36.2 | 19.2 ± 1.82 | 10.0 ± 1.59 | 9192 ± 706 | 34.9 ± 4.97 | 1.30 ± 0.13 | 8.61 ± 0.71 | |
| Ipratropium | 3.95 ± 0.44 | 207 ± 26.1 | 9.37 ± 0.83 | 4621 ± 766 | 10.8 ± 1.76 | 8.66 ± 1.95 | 28.9 ± 3.95 | ||
| Trospium | 3.31 ± 0.43 | 270 ± 42.6 | 20.6 ± 1.35 | 10,685 ± 1093 | 18.5 ± 2.48 | 5.99 ± 0.48 | 18.1 ± 4.88 | ||
| Methylnaltrexone | 1.21 ± 0.15 | 448 ± 40.9 | 17.3 ± 1.01 | 14.7 ± 1.95 | 6834 ± 1203 | 19.0 ± 4.36 | 2.69 ± 0.52 | 8.67 ± 1.48 | |
| Metformin | 0.75 ± 0.18 | 604 ± 42.3 | 17.4 ± 1.95 | 12.4 ± 3.14 | 41.7 ± 6.65 | 2.61 ± 0.48 | 11.2 ± 1.48 | ||
| Minimum | 0.75 ± 0.18 | 207 ± 26.1 | 14.3 ± 2.66 | 8.14 ± 2.12 | 3277 ± 575 | 10.8 ± 1.76 | 1.30 ± 0.13 | 6.22 ± 1.48 | |
| Maximum | 5.05 ± 0.57 | 628 ± 54.7 | 51.4 ± 1.95 | 16.8 ± 2.03 | 10,685 ± 1093 | 45.0 ± 3.45 | 8.66 ± 1.95 | 28.9 ± 3.95 | |
| Range | 6.7 | 3.0 | 3.6 | 2.1 | 3.3 | 4.2 | 6.7 | 4.6 | |